This is a new application for training grant support with a single mission: the goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research. Reducing the burden of cancer in the pediatric population requires necessitates research across the entire spectrum from fundamental molecular and cellular biologic studies to translational work that bridges the gulf that separates basic research and clinical medicine to clinical investigation. Reducing the burden of cancer in pediatric populations requires broad and intensive training of academic pediatric physicians. An experienced and highly accomplished group of faculty including faculty of the Department of Pediatric Oncology at the Dana Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Children's Hospital Boston (CHB), and additional components of the Harvard Medical School constitute the training faculty for this program. This faculty encompasses basic, translational, and clinical investigation. Trainees will be selected from the combined DFCI-CHB pediatric hematology/oncology fellowship program. Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 40 years the DFCI-CHB fellowship program has trained >200 individuals, many of whom are leaders and academic pediatric medicine. The proposed T32 program will ensure the continuance and further development of the fellowship program, and promises to contribute immeasurably to the management of children with cancer. While great strides have been made in diagnosis and treatment of pediatric cancers, much remains to be done. Cure of patients is often achieved with unacceptable side-effects, and for many solid tumors current therapy is inadequate. The best hope for reducing the burden of pediatric cancer is the training of committed researchers by an experienced and accomplished faculty that is involved in diverse aspects of basic and clinical research directly relevant to tackling these challenging problems in children.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ozuah, Nmazuo W; Marcus, Karen J; LaCasce, Ann S et al. (2017) Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. J Pediatr Hematol Oncol :
Marron, Jonathan M; Cronin, Angel M; Kang, Tammy I et al. (2017) Intended and unintended consequences: Ethics, communication, and prognostic disclosure in pediatric oncology. Cancer :
Marron, Jonathan M; DuBois, Steven G; Glade Bender, Julia et al. (2016) Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer 63:1974-82
Venkatramani, Rajkumar; Pan, Hubert; Furman, Wayne L et al. (2016) Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer 63:465-70
Cohen, Barrie; Roth, Michael; Marron, Jonathan M et al. (2016) Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Ann Surg Oncol 23:990-997
Hong, Andrew L; Tseng, Yuen-Yi; Cowley, Glenn S et al. (2016) Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun 7:11987
Greenzang, Katie A; Cronin, Angel M; Mack, Jennifer W (2016) Parental preparedness for late effects and long-term quality of life in survivors of childhood cancer. Cancer 122:2587-94
Wu, Shuo-Chieh; Li, Loretta S; Kopp, Nadja et al. (2015) Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell 28:29-41
Wu, Jennifer N; Pinello, Luca; Yissachar, Elinor et al. (2015) Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia. Epigenetics Chromatin 8:53
Marron, Jonathan M; Mack, Jennifer W (2015) When to say when: How aggressively to care for children with multiply relapsed cancer? Pediatr Blood Cancer 62:1119-20

Showing the most recent 10 out of 13 publications